Clinical Trial Detail

NCT ID NCT01781429
Title Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors BioMed Valley Discoveries, Inc
Indications

Advanced Solid Tumor

Therapies

Ulixertinib

Age Groups: adult

Additional content available in CKB BOOST